Se-Methylselenocysteine

Se-Methylselenocysteine, a precursor of Methylselenol, has potent cancer chemopreventive activity and anti-oxidant activity. Se-Methylselenocysteine is orally bioavailable, and induces apoptosis^[1][2]. In Vitro: Se-Methylselenocysteine (100-400 μM; 3 days) induces apoptosis in SKOV-33 cells^[1].
Se-Methylselenocysteine (100-400 μM; 3 days) induces caspase-3 mediated apoptosis^[1]. In Vivo: Se-Methylselenocysteine (0.2 mg/mouse; p.o.; daily for 14 days) potentiates the antitumour activity of CDDP and Cyclophosphamide in nude mice bearing human FaDu and A253 head and neck xenografts^[2].
Alzheimer's disease (AD) mice are treats with Se-Methylselenocysteine (0.75 mg/kg BW per day) in their drinking water for 10 months. Se-Methylselenocysteine reduces oxidative stress and neuro-inflammation; Se-Methylselenocysteine modulates the distribution and levels of several metal ions; Se-Methylselenocysteine decreases amyloid-β peptide (Aβ) generation by inhibiting the expression of its precursor protein APP and β-secretase (BACE1), and attenuates tau hyperphosphorylation and neurofibrillary tangles (NFT) formation via promoting protein phosphatase 2A (PP2A) activity, thereby preserving synaptic proteins and neuron activities and finally improving spatial learning and memory deficits in AD model mice^[3].